Magle Chemoswed Holding AB (publ) (FRA:52X)

Market Cap	32.79M
Revenue (ttm)	27.18M
Net Income (ttm)	-2.41M
Shares Out	n/a
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	21.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.650
Previous Close	1.600
Day's Range	1.590 - 1.650
52-Week Range	1.510 - 2.960
Beta	n/a
RSI	46.42
Earnings Date	Feb 27, 2026

About FRA:52X

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical dev...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1944
• Employees: 147
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 52X

Financial Performance

In 2024, FRA:52X's revenue was 240.57 million, an increase of 40.27% compared to the previous year's 171.50 million. Earnings were 11.94 million, a decrease of -1.91%.

Financial numbers in SEK